Recently, Moro-Sibilot et al.1 presented the results of the AcSé study that evaluated the efficacy of crizotinib in non-small-cell lung cancer (NSCLC) with ROS1 fusions and c-MET mutations or overexpressions. The excellent performance of crizotinib in ROS1 fusions was confirmed. Nevertheless, in the c-MET cohort there was a lack of activity which was not sufficient to justify its use as targeted therapy in this population. Similar results were found in the analogous METROS trial.2
Despite this evidence, we present a case where crizotinib showed clinical activity, even in a life-threatening condition, thanks to double anaplastic lymphoma kinase (ALK) and c-MET inhibition. READ ARTICLE
Annals of Oncology DOI:10.1016/j.annonc.2019.11.016
Authors: M.Mazzotta, M.Filetti, A.Rossi, M.Roberto, M.Occhipinti, A.Pernazza, A.Di Napoli, S.Scarpino, A.Vecchione, R.Giusti, P.Marchetti